199 related articles for article (PubMed ID: 12182231)
1. Tumor cell-based vaccination in renal cell carcinoma: rationale. approaches, and recent clinical development.
Volk J; Sel S; Ganser A; Schöffski P
Curr Drug Targets; 2002 Oct; 3(5):401-8. PubMed ID: 12182231
[TBL] [Abstract][Full Text] [Related]
2. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer.
Barbuto JA; Ensina LF; Neves AR; Bergami-Santos P; Leite KR; Marques R; Costa F; Martins SC; Camara-Lopes LH; Buzaid AC
Cancer Immunol Immunother; 2004 Dec; 53(12):1111-8. PubMed ID: 15185011
[TBL] [Abstract][Full Text] [Related]
4. Tumor vaccines: from gene therapy to dendritic cells--the emerging frontier.
Vieweg J; Dannull J
Urol Clin North Am; 2003 Aug; 30(3):633-43, x. PubMed ID: 12953761
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-based vaccination for renal cell carcinoma: challenges in clinical trials.
Wang J; Liao L; Tan J
Immunotherapy; 2012 Oct; 4(10):1031-42. PubMed ID: 23148755
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.
Märten A; Renoth S; Heinicke T; Albers P; Pauli A; Mey U; Caspari R; Flieger D; Hanfland P; Von Ruecker A; Eis-Hübinger AM; Müller S; Schwaner I; Lohmann U; Heylmann G; Sauerbruch T; Schmidt-Wolf IG
Hum Gene Ther; 2003 Mar; 14(5):483-94. PubMed ID: 12691613
[TBL] [Abstract][Full Text] [Related]
7. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids.
Kugler A; Stuhler G; Walden P; Zöller G; Zobywalski A; Brossart P; Trefzer U; Ullrich S; Müller CA; Becker V; Gross AJ; Hemmerlein B; Kanz L; Müller GA; Ringert RH
Nat Med; 2000 Mar; 6(3):332-6. PubMed ID: 10700237
[TBL] [Abstract][Full Text] [Related]
8. B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma.
Antonia SJ; Seigne JD
World J Urol; 2000 Apr; 18(2):157-63. PubMed ID: 10854153
[TBL] [Abstract][Full Text] [Related]
9. Enhancing whole-tumor cell vaccination by engaging innate immune system through NY-ESO-1/dendritic cell interactions.
Xu L; Zheng J; Nguyen DH; Luong QT; Zeng G
J Immunother; 2013 Oct; 36(8):412-22. PubMed ID: 23994888
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.
Pandha HS; John RJ; Hutchinson J; James N; Whelan M; Corbishley C; Dalgleish AG
BJU Int; 2004 Aug; 94(3):412-8. PubMed ID: 15291878
[TBL] [Abstract][Full Text] [Related]
11. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.
Su Z; Dannull J; Heiser A; Yancey D; Pruitt S; Madden J; Coleman D; Niedzwiecki D; Gilboa E; Vieweg J
Cancer Res; 2003 May; 63(9):2127-33. PubMed ID: 12727829
[TBL] [Abstract][Full Text] [Related]
12. Vaccination strategies in patients with renal cell carcinoma.
Asemissen AM; Brossart P
Cancer Immunol Immunother; 2009 Jul; 58(7):1169-74. PubMed ID: 19360405
[TBL] [Abstract][Full Text] [Related]
13. Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?
Brookman-May S; May M; Gilfrich C; Wieland WF; Burger M
Expert Rev Anticancer Ther; 2010 Jun; 10(6):813-23. PubMed ID: 20553207
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma.
Berntsen A; Geertsen PF; Svane IM
Eur Urol; 2006 Jul; 50(1):34-43. PubMed ID: 16675096
[TBL] [Abstract][Full Text] [Related]
15. [Tumor cell vaccination for treatment of renal cell carcinoma].
Kriegmair M; Oberneder R
Urologe A; 1995 May; 34(3):204-7. PubMed ID: 7610513
[TBL] [Abstract][Full Text] [Related]
16. Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine.
Webster WS; Thompson RH; Harris KJ; Frigola X; Kuntz S; Inman BA; Dong H
J Immunol; 2007 Sep; 179(5):2860-9. PubMed ID: 17709500
[TBL] [Abstract][Full Text] [Related]
17. IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy.
Rausch S; Kruck S; Stenzl A; Bedke J
Future Oncol; 2014 May; 10(6):937-48. PubMed ID: 24941980
[TBL] [Abstract][Full Text] [Related]
18. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
19. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma.
Rieser C; Ramoner R; Höltl L; Rogatsch H; Papesh C; Stenzl A; Bartsch G; Thurnher M
Urol Int; 1999; 63(3):151-9. PubMed ID: 10738185
[TBL] [Abstract][Full Text] [Related]
20. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.
Laurell A; Lönnemark M; Brekkan E; Magnusson A; Tolf A; Wallgren AC; Andersson B; Adamson L; Kiessling R; Karlsson-Parra A
J Immunother Cancer; 2017; 5():52. PubMed ID: 28642820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
